PERCEIVED NEED FOR PARENTERAL AMPHOTERICIN-B AFTER PROPHYLAXIS IN NEUTROPENIC PATIENTS

5 10 20 30 4 0 50 60%

perceived need for empiric amphotericin B

incidence of invasive fungal infections

USA

Europe

Previous slide

Next slide

Back to first slide

View graphic version